{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"10th European Congress on Perspectives in Lung Cancer, Brussels","description":"Silvia Novello and Giorgio Scagliotti on harnessing  insulin-like growth factor receptor inhibition in a Phase II study that showed  clinical activity of figitumumab to be at least as good as that of inhibitors of  other growth factors already being used in cancer.","author_name":"OT Broadcast News","author_url":"http:\/\/www.oncology-times.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1109875\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1109875"}